OncoCyte (OCX) Competitors $3.37 -0.07 (-2.03%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.36 -0.01 (-0.30%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCX vs. PHAT, ATYR, TRDA, CGC, IMMP, AURA, DBVT, HRTX, CMPX, and ACBShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Phathom Pharmaceuticals (PHAT), Atyr PHARMA (ATYR), Entrada Therapeutics (TRDA), Canopy Growth (CGC), Immutep (IMMP), Aura Biosciences (AURA), DBV Technologies (DBVT), Heron Therapeutics (HRTX), Compass Therapeutics (CMPX), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Phathom Pharmaceuticals Atyr PHARMA Entrada Therapeutics Canopy Growth Immutep Aura Biosciences DBV Technologies Heron Therapeutics Compass Therapeutics Aurora Cannabis OncoCyte (NASDAQ:OCX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking. Which has higher valuation & earnings, OCX or PHAT? OncoCyte has higher earnings, but lower revenue than Phathom Pharmaceuticals. OncoCyte is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncoCyte$3.84M25.08-$27.78M-$3.53-0.95Phathom Pharmaceuticals$81.86M3.43-$201.59M-$5.24-0.77 Do analysts recommend OCX or PHAT? OncoCyte presently has a consensus target price of $6.06, suggesting a potential upside of 79.90%. Phathom Pharmaceuticals has a consensus target price of $17.60, suggesting a potential upside of 337.81%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OncoCyte 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, OCX or PHAT? OncoCyte has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Does the MarketBeat Community prefer OCX or PHAT? Phathom Pharmaceuticals received 85 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 72.46% of users gave Phathom Pharmaceuticals an outperform vote while only 12.82% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformOncoCyteOutperform Votes1512.82%Underperform Votes10287.18% Phathom PharmaceuticalsOutperform Votes10072.46% Underperform Votes3827.54% Do institutionals and insiders believe in OCX or PHAT? 55.3% of OncoCyte shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 1.6% of OncoCyte shares are held by company insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer OCX or PHAT? In the previous week, OncoCyte had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 6 mentions for OncoCyte and 4 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.57 beat OncoCyte's score of 0.84 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OncoCyte 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is OCX or PHAT more profitable? Phathom Pharmaceuticals has a net margin of -1,292.14% compared to OncoCyte's net margin of -6,122.29%. Phathom Pharmaceuticals' return on equity of 0.00% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets OncoCyte-6,122.29% -269.32% -59.71% Phathom Pharmaceuticals -1,292.14%N/A -79.57% SummaryPhathom Pharmaceuticals beats OncoCyte on 13 of the 19 factors compared between the two stocks. Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.38M$2.60B$5.34B$8.30BDividend YieldN/A0.73%5.27%4.11%P/E Ratio-0.957.4126.9619.59Price / Sales25.0834.45398.83136.02Price / CashN/A15.7538.3234.64Price / Book1.365.296.774.50Net Income-$27.78M-$65.73M$3.24B$248.60M7 Day Performance20.79%-0.80%0.27%-0.89%1 Month Performance-2.03%-4.33%5.91%7.41%1 Year Performance19.08%-18.64%18.83%8.56% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte2.4823 of 5 stars$3.37-2.0%$6.06+79.9%+19.1%$96.38M$3.84M-0.95120Analyst ForecastPHATPhathom Pharmaceuticals4.015 of 5 stars$4.39+7.3%$17.60+300.9%-61.7%$306.48M$81.86M-0.77110Positive NewsGap DownATYRAtyr PHARMA2.828 of 5 stars$3.44+5.2%$18.60+440.7%N/A$306.17M$235,000.00-3.6653Positive NewsTRDAEntrada Therapeutics3.1319 of 5 stars$8.01-1.0%$25.67+220.4%-50.4%$304.00M$172.22M5.04110News CoverageAnalyst ForecastAnalyst RevisionCGCCanopy Growth0.8647 of 5 stars$1.64-1.2%$2.00+22.0%-80.1%$301.54M$276.75M-0.433,150Trending NewsUpcoming EarningsIMMPImmutep1.3161 of 5 stars$2.04+0.5%$7.00+243.1%-31.7%$297.92M$5.14M0.002,021Analyst UpgradeGap DownAURAAura Biosciences2.628 of 5 stars$5.92-0.5%$22.75+284.3%-16.2%$297.33MN/A-3.4250News CoverageAnalyst ForecastInsider TradeGap DownDBVTDBV Technologies2.4488 of 5 stars$10.80-2.7%$15.50+43.5%+40.2%$295.81M$15.73M-2.4080HRTXHeron Therapeutics3.5779 of 5 stars$1.92-2.5%$5.50+186.5%-46.2%$292.92M$148.52M-10.67300Positive NewsAnalyst DowngradeCMPXCompass Therapeutics3.9275 of 5 stars$2.11+0.5%$13.13+522.0%+42.2%$291.78M$850,000.00-5.7020Gap DownACBAurora Cannabis0.7325 of 5 stars$5.02-2.1%N/A-17.4%$282.19M$320.81M100.421,340Positive NewsGap Down Related Companies and Tools Related Companies Phathom Pharmaceuticals Alternatives Atyr PHARMA Alternatives Entrada Therapeutics Alternatives Canopy Growth Alternatives Immutep Alternatives Aura Biosciences Alternatives DBV Technologies Alternatives Heron Therapeutics Alternatives Compass Therapeutics Alternatives Aurora Cannabis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCX) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCX Stock Free OCX Stock Alerts